Dr. Muniz is member of the Certara Board of Directors and Chair of the Board’s Science Committee, which is responsible for advancing Certara’s scientific strategy, monitoring the company’s scientific capabilities, assessing and driving new scientific initiatives, and supporting breakthrough scientific projects. Dr. Muniz served as CEO of Certara from June, 2014 to May, 2019, during which time he established the vision and strategy that has resulted in Certara becoming the world leader in model-informed drug development.
During his twenty-five-year scientific and business management career, he has held multiple senior executive roles in the pharmaceutical industry and public health organizations. Among these roles, Dr. Muniz served as Head of Worldwide Pharmacovigilance and Epidemiology, Cardiovascular Business Unit Leader, and Vice President of Global Oncology Clinical Development at Eli Lilly and Company.
Dr. Muniz earned an MD degree from the Autonomous University of Santo Domingo in the Dominican Republic, a PhD in Population Planning and International Health and an MS in Population Planning, both from the University of Michigan. He is also a graduate of the Epidemic Intelligence Service Program and the Preventive Medicine and Public Health Fellowship at the Centers for Disease Control and Prevention in Atlanta, Georgia.